Literature DB >> 32016269

VE-cadherin fusion protein substrate enhanced the vasculogenic mimicry capability of hepatocellular carcinoma cells.

Qizhi Shuai1, Lei Cao1, Zheng Qin1, Yan Zhang2, Zhongwei Gu3, Jun Yang1.   

Abstract

To investigate the VE-cadherin-based intercellular crosstalk in tumor cells, a fusion protein consisting of a human VE-cadherin extracellular domain and an immunoglobulin G Fc region (hVE-cad-Fc) was prepared as an artificial extracellular matrix (ECM) for the culture of hepatocellular carcinoma cells (Bel7402 cells). Compared with cells cultured on TCPS and collagen coated plates, the Bel7402 cells cultured on a series concentration of hVE-cad-Fc coated plates showed elongated morphology, inhibited proliferation, and significantly enhanced migration and secretion of ECM compounds and cytokines in a concentration-dependent manner. When the concentration of hVE-cad-Fc reached 15 μg mL-1, the Bel7402 cells formed a patterned network with positive-staining of PAS. The high-density hVE-cad-Fc substrate markedly elevated the expression of endogenous VE-cadherin and EphA2, and subsequently activated the intracellular signal transduction pathways including VE-cadherin/PI3K/MMPs and VE-cadherin/EphA2/FAK/p-VE-cadherin axes as well as epithelial-mesenchymal transition (EMT). Therefore, the high-density hVE-cad-Fc substrate was able to induce the vasculogenic mimicry (VM) formation of Bel7402 cells, and exhibit the potential for the construction of an in vitro tumor model of VM. Moreover, hVE-cad-Fc appeared to be a promising candidate for the investigation of VE-cadherin mediated cell-cell interactions in tumor development.

Entities:  

Year:  2020        PMID: 32016269     DOI: 10.1039/c9tb02790d

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  1 in total

1.  COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis.

Authors:  Zewen Chu; Xin Shi; Gaoyang Chen; Xuejun He; Yayun Qian; Haibo Wang; Li Tao; Yanqing Liu; Wei Jiang; Jue Chen
Journal:  Front Pharmacol       Date:  2021-03-31       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.